GXV813

DRUG2 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Schizophrenia

Phase 2

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

RecruitingNCT07467993

Novartis PharmaceuticalsSchizophrenia

Start: 2026-03-16End: 2027-07-29Target: 142Updated: 2026-07-29

A Phase 2a, Randomized, Participant- and Investigator blinded, Parallel-group, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults with DSM-5 Schizophrenia (STAR-1)

Not yet recruitingCTIS2025-524058-32-00

Novartis Pharma AGSchizophrenia

Target: 42Updated: 2026-04-29